Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation-induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs in some patients. However, inhibitory immune molecules, including programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1), within the MCC tumor microenvironment aid in tumor evasion of T-cell-mediated clearance. Unlike chemotherapy, treatment with anti-PD-L1 (avelumab) or anti-PD-1 (pembrolizumab) antibodies leads to durable responses in MCC, in both virus-positive and virus-negative tumors. As many tumors are established through the evasion of infiltrating immune-cell clearance, the lessons learned in MCC may be broadly relevant to many cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 1×
“cells upregulates inhibitory receptors on active T cells, causing T cells to lose functionality over time.(89) Increased expression of the T-cell receptors PD-1 and TIM-3 occurs in response to”
BackgroundClonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“maintenance of self-tolerance, as evidenced by the development of autoimmune disorders in PD-1 null mice.(88) However, chronic antigen stimulation from viral infections and tumor”
BackgroundMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · cited 1×
“PD-L1 expression is induced by type II interferons, which can be produced in the tumor microenvironment by activated T cells and NK cells.(96,98) Following the activation of the adaptive immune response to foreign antigens, the expression of PD-L1 serves to reinstate immune homeostasis and protect tissue from cytotoxi…”
BackgroundSeiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“squamous cell carcinoma, another tumor with a viral etiology.(111) Anti–PD-1 and anti–PD-L1 antibodies have been inves-”
BackgroundFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · cited 3×
“Pembrolizumab is a humanized IgG4 anti–PD-1 monoclonal antibody (Table 2).(8) Pembrolizumab has been investigated as first-line treatment of immunocompetent patients with”
BackgroundSelf-citation
Cited by
D’Angelo, S. P., Russell, J., Lebbé, C., Chmielowski, B., Gambichler, T., Grob, J.-J., Kiecker, F., Rabinowits, G., Terheyden, P., Zwiener, I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0077 · Cited by 377
Self-citationKaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334
“3); these patients might be more likely to be immunocompetent and thus more responsive to immune checkpoint inhibitor treatment [16].”
BackgroundBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
“The Merkel cell cancers that are positive for Mpv have a very low somatic TMB (Goh et al. 2016); it is presumed that cell cancers that lack Mpv have a very high TMB (Goh et al. 2016), similar to squamous cell cancers of the skin, but with somatic mutations in TP53 and RB1 (Schadendorf et al. 2017).”
BackgroundMerkel cell carcinoma: an updated review focused on bone and bone marrow metastases
Scotti, B., Broseghini, E., Ricci, C., Corti, B., Viola, C., Misciali, C., Baraldi, C., Vaccari, S., Lambertini, M., Venturi, F., et al. (2025) · Cancers · doi:10.3390/cancers17132253 · Cited by 9
“This finding aligns with the existing literature, which highlights that incorporating surgery into multimodal treatment can be a favorable prognostic factor for disease-free survival (DFS) in MCC [207,208].”
Metadata
- Authors
- Schadendorf, D., Nghiem, P., Bhatia, S., Hauschild, A., Saiag, P., Mahnke, L., Hariharan, S., & Kaufman, H. L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-08-31
- Volume
- 6
- Issue
- 10
- Pages
- e1338237
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2750984295
- Cited by
- 62
- References
- 14
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. https://app.cochat.ai/papers/10.1080/2162402x.2017.1338237
- The paper
- Schadendorf, D., Nghiem, P., Bhatia, S., Hauschild, A., Saiag, P., Mahnke, L., Hariharan, S., & Kaufman, H. L. (2017). Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology. https://doi.org/10.1080/2162402x.2017.1338237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.